title: [Immunotherapy of gastric cancer].
abstract: Two immunotherapeutic methods were developed as adjuvant therapy for gastrointestinal malignancies, one using oral administration of a streptococcal preparation, OK-432, and the other with adoptive immunotherapy (AIT), local transfer of IL2-cultured and autologous lymphocytes, combined with local preadministration of OK-432. Tsuchitani and Nio in our laboratory have revealed experimentally that oral OK-432 stimulates tumor-specific and non-specific immune mechanisms of gut-associated lymphoid tissues and inhibits the growth of some murine syngeneic tumors that were transplanted into cecal patches. The clinical efficacy of oral OK-432 on gastric cancer patients has been examined by a controlled randomized trial involving a total of about 1000 cases. Oral OK-432 (5KE, once a week) was revealed to be significantly effective in curatively resected group but not effective in non-curatively resected group. Ten consecutive patients with peritoneal dissemination of gastric cancer were treated with intraperitoneal OK-432 and AIT. AIT was performed by transferring autologous lymph node-lymphocytes cultured for 13 days with crude IL2 and tumor-extract. The survival of the treated patients was significantly longer (50% survival period exceeded 1 year) than that of historical control (95 cases, 50% survival period was 5 months). These immunotherapeutic methods are expected to be useful for multidisciplinary therapy of gastric cancer by a combination of each method with other therapeutic methods.
authors.affiliation: 1st Dept. of Surgery, Kyoto University, Faculty of Medicine.
authors.forename: N
authors.initials: N
authors.lastname: Kan
authors.forename: K
authors.initials: K
authors.lastname: Ohgaki
authors.forename: T
authors.initials: T
authors.lastname: Okino
authors.forename: M
authors.initials: M
authors.lastname: Nakanishi
authors.forename: Y
authors.initials: Y
authors.lastname: Nio
authors.forename: K
authors.initials: K
authors.lastname: Inoue
authors.forename: T
authors.initials: T
authors.lastname: Tobe
mesh_terms: D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007116:Immunization, Passive; D010844:Picibanil / Q000627:therapeutic use*; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000601:surgery / Q000628:therapy*
chemical_list: D001688:Biological Products; D010844:Picibanil